

## CURRENTLY ACTIVE CLINICAL TRIALS

### GLAUCOMA AREA

SPONSOR	TRIAL NAME	PROTOCOL CODE	
	HYDRUS 3	CP-10-002	A prospective randomized multicenter trial comparing the Hydrus Aqueous implant with the IStent™ to lower intraocular pressure in glaucoma patients undergoing cataract surgery (Hydrus III).
	HYDRUS 4	CP-11-001	Safety and efficacy of the Hydrus™ aqueous implant to reduce intraocular pressure in glaucoma patients undergoing cataract surgery. A prospective, multicenter, randomized controlled trial (Hydrus4 study).
	HYDRUS 5	CP-12-001 HYDRUS V	Prospective, multicenter and randomized comparison of Hydrus™ with IStent™ to reduce intraocular pressure in primary open-angle glaucoma.
	HYDRUS 7	CP-16-001 HYDRUS VII	The Hydrus microstent for refractory open-angle glaucoma: a prospective, multicenter clinical trial.
	ARTEMIS	192024-091	Efficacy and safety of slow-release Bimatoprost in patients with open-angle glaucoma or ocular hypertension.
	PIROMELATINA	Piromelatine-IOP1	Randomized, double-blind, placebo-controlled study of oral therapy with pyromelatin in patients with ocular hypertension (HTO) or with primary open-angle glaucoma (APAG).
	MERCURY - 3	Mercury - 3	A prospective, double-masked, randomized, multicenter, active comparator with parallel groups of 6 months duration to evaluate the safety and efficacy of ocular hypotensive agent PG324 ophthalmic solution compared to GANFORT® (bimatoprost 0.03% / timolol 0.5%) ophthalmic solution in subjects with elevated intraocular pressure (MERCURY 3)
	GLJ576-P001	Protocol Training QVJ499A2402	Multicenter, randomized, masked study. Double and parallel groups to demonstrate the reducing effect of IOP with 1% brinzolamide/0.2% brimonidine (administered twice daily) when added to the 0.004% travoprost/0.5% timolol solution in subjects with open-angle glaucoma or ocular hypertension.

